Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

A new study suggests belly fat could increase the ... Weight loss drugs such as Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) could be crucial treatment options for patients looking to keep ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly says a new starting dose regimen for ... and other anti-amyloid drugs and can be life-threatening. In the new study, there was also a larger 67% reduction in ARIA-E among patients ...

According to the study, which was published Monday in Nature Medicine, researchers found that use of the new medicines may ... Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists ...

Last year, the medicine aced a phase 3 study in which it delayed ... including several new ones. Over the past two years, Eli Lilly has earned approval for such products as Alzheimer's disease ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... a lot of weight could put them at risk for that disease, but a new study suggests that could indeed be the case. According to a recent study ...